Thyroid Nodule with a Suspicious Ultrasound Pattern in a Young Woman
A 29-year-old woman is referred with a 2.4 cm left thyroid nodule found incidentally on a neck ultrasound performed for lymphadenopathy during a viral illness. The ultrasound shows a solid, hypoechoic nodule with irregular margins, microcalcifications, and a taller-than-wide shape. There is a 0.9 cm left level III lymph node with loss of the fatty hilum and internal calcification. She is euthyroid, has no family history of thyroid cancer, and has no hoarseness. Fine-needle aspiration of the nodule is reported as Bethesda category III (atypical cells of undetermined significance). The endocrine team asks whether she should have surgery now or repeat biopsy.
1. Interpret the ultrasound features and the lymph node findings, and explain what they imply about the probability of malignancy.
Read the worked answer
The nodule shows multiple high-risk features: solid composition, hypoechogenicity, irregular margins, microcalcifications, and a taller-than-wide shape. These are the classic suspicious sonographic features associated with papillary thyroid carcinoma, and the combination places the nodule in a high-risk ultrasound category with a malignancy risk well above 50-70%. The left level III node is abnormal: loss of the fatty hilum and internal calcification are suspicious for metastatic papillary carcinoma, particularly when calcification is present, which is characteristic of psammoma bodies. The node is small (0.9 cm) but its morphology matters more than size. Taken together, the findings suggest a probable papillary thyroid carcinoma with regional nodal metastasis, and the Bethesda III cytology is discordant with the high sonographic suspicion, which should prompt further evaluation rather than reassurance.
2. Given the Bethesda III result, what are the options and which would you recommend?
Read the worked answer
Options include repeat fine-needle aspiration, molecular testing on the residual sample, diagnostic hemithyroidectomy, or immediate total thyroidectomy with central and lateral neck dissection. Repeat FNA is reasonable when the initial sample was scant or technically difficult, but here the ultrasound is highly suspicious and a repeat may again be indeterminate. Molecular testing can reclassify risk: BRAF V600E and other mutations increase the probability of malignancy and support surgery, while a benign expression classifier can support observation in selected cases. However, the suspicious lymph node changes the calculus, because nodal metastasis is itself an indication for surgery and for lateral neck dissection. My recommendation is surgical referral for total thyroidectomy with central and left lateral neck dissection, with confirmation of the nodal status by ultrasound-guided FNA of the node and thyroglobulin washout if the result would change the extent of surgery. Repeat nodule biopsy alone would not address the node and would delay definitive treatment.
3. What would change if the lymph node were normal on ultrasound and the nodule were 1.2 cm?
Read the worked answer
With a normal node and a 1.2 cm nodule, the size no longer mandates immediate surgery on its own, but the suspicious ultrasound features still matter. A 1.2 cm nodule with irregular margins, microcalcifications, and a taller-than-wide shape remains high risk, and Bethesda III cytology in that setting still carries a substantial malignancy rate. Options include repeat FNA, molecular testing, or diagnostic hemithyroidectomy. Active surveillance is generally reserved for small papillary microcarcinomas under 1 cm without suspicious features, so it would not be appropriate here. I would favour molecular testing if available to refine risk, with hemithyroidectomy if the mutation profile is high risk or if the patient prefers definitive diagnosis. The key judgement is that size alone does not determine management; the sonographic pattern, cytology category, nodal status, and patient preference together drive the decision.